Studies have demonstrated that ADAM12 is overexpressed in triple-negative breast cancer tissues and cell lines and that the overexpression of ADAM12 in triple-negative breast cancer is partially mediated by DNA hypomethylation, an epigenetic alteration that has a significant impact on OS in triple-negative breast cancer patients [40]. The gene discussed is ADAM12; the disease is triple-negative breast carcinoma.